Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo

Area of Science:

• Hepatocellular Carcinoma (HCC) Research
• RNA Therapeutics
• Gene Expression Regulation

Background:

• Hepatocellular carcinoma (HCC) predominantly affects patients with liver cirrhosis.
• Current treatments for HCC in cirrhotic patients have limitations.
• There is a need for innovative therapies that address both tumor burden and liver function.

Purpose of the Study:

• To develop and evaluate an RNA-based therapy to enhance albumin production and reduce liver tumor burden.
• To investigate the role of C/EBPα (CCAAT/enhancer-binding protein-α) in regulating albumin expression and cell proliferation in HCC.
• To assess the therapeutic potential of short-activating RNAs (saRNA) targeting C/EBPα in a preclinical model of liver cirrhosis and HCC.

Main Methods:

• Designed short-activating RNAs (saRNA) to enhance C/EBPα expression.
• Transfected HepG2 cells with C/EBPα-saRNA to assess albumin production and cell proliferation.
• Administered C/EBPα-saRNA intravenously in a cirrhotic rat model with liver tumors.
• Utilized microarray analysis, quantitative PCR, and western blot to analyze gene expression changes.

Main Results:

• C/EBPα-saRNA transfection increased C/EBPα and albumin mRNA levels, leading to a 3-fold increase in albumin secretion and a 50% decrease in HepG2 cell proliferation.
• In cirrhotic rats, C/EBPα-saRNA increased serum albumin by over 30% and reduced tumor burden by 80%.
• Gene expression analysis revealed downregulation of genes associated with apoptosis, angiogenesis, and metastasis, and upregulation of tumor suppressors and differentiation markers.

Conclusions:

• A novel injectable saRNA-oligonucleotide targeting C/EBPα enhances albumin production.
• This saRNA therapy effectively reduces tumor burden in a preclinical liver cirrhosis/HCC model.
• The approach demonstrates potential for simultaneously improving liver function and decreasing tumor burden in HCC.